drugset / Trial / NCT03765762
A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will evaluate the safety, tolerability, and potential cognitive benefit of the experimental treatment GRF6019 in subjects with severe Alzheimer's disease.
Timeline
- Start
- 2019-01-15
- Primary completion
- 2019-12-17
- Completion
- 2019-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRF6019 | Protein / enzyme biologic | 250 ml | Intravenous |